Which funds bought or sold AZN in Q3 2026?
Astrazeneca Plc. 10 funds bought, 7 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was +$608M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- D. E. Shaw+$594M
- Wellington+$374M
- Capital Research+$185M
- Capital World+$165M
- Point72+$154M
- State Street+$119M
- Amundi+$113M
- Marshall Wace+$103M
- Temasek+$70M
- Fisher Investments+$57M
- Ameriprise−$155M
- AllianceBernstein−$132M
- Northern Trust−$66M
- Jennison−$31M
- Farallon−$22M
- Glenview−$9M
- GQG−$6M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (10)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| D. E. Shaw Quant & multi-strategy | Added+336.3% | +$594M | $771M |
| Wellington Asset manager | Added+8.1% | +$374M | $5.0B |
| Capital Research Asset manager | Added+27% | +$185M | $867M |
| Capital World Asset manager | Added+3.4% | +$165M | $5.1B |
| Point72 Quant & multi-strategy | Added+134.4% | +$154M | $269M |
| State Street Index giant | Added+283.7% | +$119M | $161M |
| Amundi Asset manager | Added+4.3% | +$113M | $2.8B |
| Marshall Wace Quant & multi-strategy | Added+75.6% | +$103M | $238M |
| Temasek Sovereign & pension | Added+77.3% | +$70M | $160M |
| Fisher Investments Asset manager | Added+3.2% | +$57M | $1.9B |
Sold (7)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Ameriprise Asset manager | Trimmed-15.8% | −$155M | $828M |
| AllianceBernstein Asset manager | Trimmed-18.6% | −$132M | $576M |
| Northern Trust Bank & broker | Trimmed-17.7% | −$66M | $307M |
| Jennison Growth / crossover | Trimmed-28.9% | −$31M | $77M |
| Farallon Hedge fund | Trimmed-23.3% | −$22M | $71M |
| Glenview Hedge fund | Trimmed-31.8% | −$9M | $20M |
| GQG Growth / crossover | Trimmed-85.4% | −$6M | $1M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.